TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. (Nasdaq: MTAC) is a medical device company in the interventional oncology sector that emerged from a business combination with MedTech Acquisition Corp, a healthcare-focused special purpose acquisition company that completed its initial public offering in 2021. TriSalus develops pressure-enabled drug delivery technology, including its TriNav Infusion System, designed to improve the delivery of chemotherapy agents to primary and metastatic liver tumors. The company filed an 8-K with the SEC on May 14, 2026, reflecting its status as an active reporting issuer following the de-SPAC transaction. For complete data on MTAC's SPAC origins, deal history, and ongoing filings, sign up for full access at SpacDesk.